Vupanorsen (Pfizer-led clinical development programme discontinued in January 2022)

Ongoing Trials

TRANSLATE-TIMI 70

Completed Trials

Phase 2, dose-ranging study of vupanorsen in patients with diabetes, hepatic steatosis and hypertriglyceridaemia (NCT03371355)

Educational partners and supporters